This segment focuses on the development, manufacturing, and commercialization of inhaled therapeutic products for diabetes management. The primary product in this segment is Afrezza, an inhaled insulin designed to improve glycemic control in adults with diabetes. Research and development activities include optimizing the formulation and delivery of inhaled insulin, as well as exploring new applications and patient populations. The technology utilized is based on the company's proprietary Technosphere® technology, which enables rapid absorption of insulin through the lungs. This segment addresses the needs of patients seeking a faster-acting and more convenient insulin delivery method, potentially improving patient outcomes and quality of life. MannKind's market positioning is based on providing an alternative to traditional injectable insulin, offering a competitive advantage through its innovative delivery system. Future opportunities include expanding the use of Afrezza and developing new inhaled therapies for diabetes and related conditions. Regulatory aspects involve obtaining and maintaining FDA approvals and adhering to stringent manufacturing standards. Partnerships and collaborations are essential for distribution and market access.

This segment is dedicated to the research, development, and commercialization of inhaled therapeutic products for orphan lung diseases. MannKind is actively involved in developing therapies for conditions with high unmet medical needs, such as pulmonary arterial hypertension (PAH) and other rare lung disorders. Research and development efforts focus on identifying and formulating effective inhaled treatments, leveraging the company's expertise in pulmonary drug delivery. The technologies employed include dry powder inhaler (DPI) formulations and the Technosphere® technology. This segment aims to improve the lives of patients suffering from rare lung diseases by providing innovative and accessible therapies. Market positioning involves targeting specific patient populations and collaborating with healthcare providers specializing in orphan lung diseases. Future opportunities include expanding the pipeline of inhaled therapies for various lung conditions and establishing strategic partnerships to accelerate product development and commercialization. Regulatory aspects involve navigating the regulatory pathways for orphan drug designation and clinical trials. Partnerships and collaborations are crucial for clinical development, manufacturing, and market access.